Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain

Gene

Volumn 315, Issue 1-2, 2003, Pages 21-32

  Zhang, Li ^a   Lin, Wei Jen ^a,b   Li, Shengwen ^a   Aoki, K Roger ^a  

^a ALLERGAN INC   (United States)

^b CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

Author keywords

BoNT A Hall; botR; HA; NTNH A Hall

Indexed keywords

AMINO ACID; BOTULINUM REGULATORY PROTEIN; BOTULINUM TOXIN; BOTULINUM TOXIN A; CASEIN KINASE II; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLYCOGEN SYNTHASE KINASE 3; HEMAGGLUTININ; HEMAGGLUTININ 17; HEMAGGLUTININ 34; HEMAGGLUTININ 70; NEUROTOXIN; NONTOXIC NONHEMAGGLUTININ; PROTEIN; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; TOXIN; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM BOTULINUM TYPE A; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SEROTYPE;

CLOSTRIDIUM; CLOSTRIDIUM BOTULINUM;

EID: 0141483181     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(03)00792-3     Document Type: Article

References (30)

1. Adler M., Keller J.E., Sheridan R.E., Deshpande S.S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon. 39:2001;233-243.
2. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon. 39:2001;1815-1820.
3. Aoki K.R. Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. 248(Suppl. 1):2001;3-10.
4. Aoki K.R., Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 8(Suppl. 5):2001;21-29.
5. Bernard C. An Introduction to the Study of Experimental Medicine. 1927;Macmillan, New York.
6. Binder W.J., Blitzer A., Brin M.F. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol. Surg. 24:1998;1198-1205.
7. Binder W.J., Brin M.F., Blitzer A., Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis. Mon. 48:2002;323-335.
8. Black J.D., Dolly J.O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals: II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell Biol. 103:1986;535-544.
9. Brashear A., Lew M.F., Dykstra D.D., Comella C.L., Factor S.A., Rodnitzky R.L., Trosch R., Singer C., Brin M.F., Murray J.J., Wallace J.D., Willmer-Hulme A., Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 53:1999;1439-1446.
10. Brin M.F., Hallett M., Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin. 2002;Lippincott Williams and Wilkins, Philadelphia.
11. Brin M.F., Lew M.F., Adler C.H., Comella C.L., Factor S.A., Jankovic J., O'Brien C., Murray J.J., Wallace J.D., Willmer-Hulme A., Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 53:1999;1431-1438.
12. Ferrer-Montiel A.V., Canaves J.M., DasGupta B.R., Wilson M.C., Montal M. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J. Biol. Chem. 271:1996;18322-18325.
13. Ferrer-Montiel A.V., Gutierrez L.M., Apland J.P., Canaves J.M., Gil A., Viniegra S., Biser J.A., Adler M., Montal M. The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking. FEBS Lett. 435:1998;84-88.
14. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 278:2003;1363-1371.
15. Gutierrez L.M., Viniegra S., Rueda J., Ferrer-Montiel A.V., Canaves J.M., Montal M. A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J. Biol. Chem. 272:1997;2634-2639.
16. Henderson I., Davis T., Elmore M., Minton N. The genetic basis of toxin production in Clostridium botulinum and Clostridium tetani. Rood J., McClane B., Songer J., Titball R. The Clostridia: Molecular Biology and Pathogenesis. 1997;261-294 Academic Press, San Diego.
17. Jankovic J., Schwartz K., Donovan D.T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry. 53:1990;633-639.
18. Johnson E.A. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53:1999;551-575.
19. Johnson J.L., Francis B.S. Taxonomy of the Clostridia: ribosomal ribonucleic acid homologies among the species. J. Gen. Microbiol. 88:1975;229-244.
20. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 456:1999;137-142.
21. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:1998;898-902.
22. Lew M.F., Adornato B.T., Duane D.D., Dykstra D.D., Factor S.A., Massey J.M., Brin M.F., Jankovic J., Rodnitzky R.L., Singer C., Swenson M.R., Tarsy D., Murray J.J., Koller M., Wallace J.D. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 49:1997;701-707.
23. Lin W.J., Johnson E.A. Transposon Tn916 mutagenesis in Clostridium botulinum. Appl. Environ. Microbiol. 57:1991;2946-2950.
24. Montecucco C., Schiavo G., Tugnoli V., de Grandis D. Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol. Med. Today. 2:1996;418-424.
25. Schantz E.J., Johnson E.A. Botulinum toxin: the story of its development for the treatment of human disease. Perspect. Biol. Med. 40:1997;317-327.
26. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80:2000;717-766.
27. Schnider P., Binder M., Kittler H., Birner P., Starkel D., Wolff K., Auff E. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br. J. Dermatol. 140:1999;677-680.
28. Simpson L.L. Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie. 82:2000;943-953.
29. Steward L.E., Fernandez-Salas E., Ho H., Sun S.W., Ordas J.V., Zhang L., Herrington T.M., Aoki K.R. BoNT/A light chain and the dileucine motif: potential implications for light chain localization and neurotoxin duration of action. Naunyn-Schmiedeberg's Archives of Pharmacology. 365(Supplement 2):2002.
30. Thompson D.E., Brehm J.K., Oultram J.D., Swinfield T.J., Shone C.C., Atkinson T., Melling J., Minton N.P. The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur. J. Biochem. 189:1990;73-81.